Date: 2017-12-17
Type of information: Research agreement
Compound:
Company: Idorsia (Switzerland) Roche (Switzerland)
Therapeutic area: Cancer - Oncology
Type agreement: research - development - R&D
Action mechanism:
Disease:
Details:
- • On December 20, 2017, Idorsia announced that it has entered into a research collaboration that provides Roche with an exclusive option right to develop and market first-in-class compounds for a promising new approach in the field of cancer immunotherapy. The parties will collaborate on the discovery of products through the formation of a joint committee, chaired by Idorsia.
Financial terms:
- Roche will pay Idorsia an upfront payment of CHF 15 million and will have the option to exclusively license Idorsia compounds and compounds resulting from the collaboration, for a further payment of 35 million, after a pre-determined period. After the exercise of its option right, Roche would have the exclusive worldwide right to develop and commercialize the Idorsia and collaboration compounds.
- Idorsia will be eligible to receive one-time development and regulatory milestones of up to CHF 410 million. Idorsia will also be entitled to one-time milestones based on sales thresholds, as well as tiered royalties on annual net sales of all products resulting from the collaboration.
Latest news:
Is general: Yes
